Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2012 - 2026)

Jazz Pharmaceuticals' Deferred Taxes history runs 15 years deep, the most recent figure standing at -$66.2 million for Q1 2026.

• On a quarterly basis, Deferred Taxes fell 51.14% year-over-year to -$66.2 million in Q1 2026; TTM through Mar 2026 was -$467.4 million, a 151.62% decrease from a year earlier, with the FY2025 full-year figure at -$445.0 million, down 113.59% from the prior year.
• Deferred Taxes eased to -$66.2 million in Q1 2026 per JAZZ's latest filing, from -$63.3 million in the prior quarter.
• Across five years, Deferred Taxes topped out at -$2.4 million in Q4 2024 and bottomed at -$271.4 million in Q3 2025.
• The 5-year median for Deferred Taxes is -$66.1 million (2023), against an average of -$74.8 million.
• Across the five-year window, Deferred Taxes soared 93.44% in 2024 and sank 2588.28% in 2025, its largest moves.
• Year by year, Deferred Taxes stood at -$145.4 million in 2022, then surged by 75.31% to -$35.9 million in 2023, then surged by 93.44% to -$2.4 million in 2024, then sank by 2588.28% to -$63.3 million in 2025, then decreased by 4.57% to -$66.2 million in 2026.
• Per Business Quant, the three latest JAZZ Deferred Taxes figures stand at -$66.2 million (Q1 2026), -$63.3 million (Q4 2025), and -$271.4 million (Q3 2025).